JP2006517970A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006517970A5 JP2006517970A5 JP2006503521A JP2006503521A JP2006517970A5 JP 2006517970 A5 JP2006517970 A5 JP 2006517970A5 JP 2006503521 A JP2006503521 A JP 2006503521A JP 2006503521 A JP2006503521 A JP 2006503521A JP 2006517970 A5 JP2006517970 A5 JP 2006517970A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- cancer
- cancer therapeutic
- antibody
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44771403P | 2003-02-14 | 2003-02-14 | |
| PCT/US2004/004116 WO2004074437A2 (en) | 2003-02-14 | 2004-02-13 | Compositions and methods for cancer immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006517970A JP2006517970A (ja) | 2006-08-03 |
| JP2006517970A5 true JP2006517970A5 (enExample) | 2007-04-05 |
Family
ID=32908487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503521A Pending JP2006517970A (ja) | 2003-02-14 | 2004-02-13 | 癌免疫療法のための組成物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US8795672B2 (enExample) |
| EP (1) | EP1599572A4 (enExample) |
| JP (1) | JP2006517970A (enExample) |
| CA (1) | CA2516028C (enExample) |
| WO (1) | WO2004074437A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2516028C (en) * | 2003-02-14 | 2012-10-16 | University Of Southern California | Conjugates comprising a cancer targeting molecule linked to a liver-expressed chemokine |
| EP1814568A4 (en) * | 2004-10-29 | 2009-08-12 | Univ Southern California | COMBINATION IMMUNOTHERAPY AGAINST CANCER WITH COSTIMULATORY MOLECULES |
| GB0525535D0 (en) * | 2005-12-15 | 2006-01-25 | Cgt Corp | Tumour treatment |
| WO2007130555A2 (en) * | 2006-05-02 | 2007-11-15 | Providence Health System | Augmentation of immune response to cancer vaccine |
| CA2656700A1 (en) * | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| EP2211903A4 (en) * | 2007-10-17 | 2011-07-06 | Nuvelo Inc | CLL-1 ANTIBODY |
| EP2262531A1 (en) * | 2008-03-08 | 2010-12-22 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| US11071754B2 (en) * | 2013-03-11 | 2021-07-27 | Case Western Reserve University | Method of generating tumor-specific T cells |
| WO2014144666A2 (en) * | 2013-03-15 | 2014-09-18 | The University Of Chicago | Methods and compositions related to t-cell activity |
| JP2016535009A (ja) * | 2013-10-17 | 2016-11-10 | チルドレンズ ホスピタル ロサンゼルス | 抗体依存性エキソソーム治療の方法 |
| KR102738546B1 (ko) * | 2014-02-19 | 2024-12-04 | 메르크 파텐트 게엠베하 | 암-표적화된 ｉｌ-12 면역요법 |
| US11371066B2 (en) | 2015-07-13 | 2022-06-28 | Modular Genetics, Inc. | Generation of acyl alcohols |
| WO2017184873A2 (en) | 2016-04-20 | 2017-10-26 | Aelan Cell Technologies, Inc. | Compositions and methods related to the methylation of histone h1.0 protein |
| EP3541931A4 (en) | 2016-11-21 | 2020-11-04 | Nant Holdings IP, LLC | COMBINED FRACTAL TREATMENT |
| AU2018237046B2 (en) | 2017-03-20 | 2024-11-14 | Cancer Therapeutics Laboratories, Inc. | Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy |
| WO2019084332A1 (en) | 2017-10-25 | 2019-05-02 | Aelan Cell Technologies, Inc. | ANTI-H1.0K180ME2 ANTIBODIES, PREPARATION METHODS AND USES THEREOF |
| US11814434B2 (en) | 2018-03-13 | 2023-11-14 | Tusk Therapeutics Ltd. | Anti-CD25 for tumour specific cell depletion |
| US20220112257A1 (en) * | 2019-01-11 | 2022-04-14 | Arbele Limited | Mul tispecific prochemokine therapeutic proteins (park) and method of making and using thereof |
| CN115397860B (zh) | 2020-05-14 | 2025-06-13 | 江苏恒瑞医药股份有限公司 | 抗cd25抗体、其抗原结合片段及其医药用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5116943A (en) * | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
| US5132405A (en) * | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) * | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| ATE155482T1 (de) * | 1990-04-06 | 1997-08-15 | Jolla Cancer Res Found | Verfahren und verbindung zur behandlung von thrombose |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ATE208633T1 (de) * | 1994-09-16 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| US5767071A (en) * | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
| US5780426A (en) * | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
| GB9814383D0 (en) | 1998-07-02 | 1998-09-02 | Cambridge Antibody Tech | Improvements relating to antibodies |
| US6365619B1 (en) | 1999-07-22 | 2002-04-02 | Novartis Ag | Treatment of arteriosclerosis |
| US6356619B1 (en) * | 2000-06-02 | 2002-03-12 | General Electric Company | Varying x-ray tube focal spot dimensions to normalize impact temperature |
| EP1392351A2 (en) * | 2001-01-24 | 2004-03-03 | Schering Corporation | Chemokines as adjuvants of immune response |
| US20040077835A1 (en) * | 2001-07-12 | 2004-04-22 | Robin Offord | Chemokine receptor modulators, production and use |
| US20030148982A1 (en) * | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| CA2516028C (en) * | 2003-02-14 | 2012-10-16 | University Of Southern California | Conjugates comprising a cancer targeting molecule linked to a liver-expressed chemokine |
-
2004
- 2004-02-13 CA CA2516028A patent/CA2516028C/en not_active Expired - Fee Related
- 2004-02-13 WO PCT/US2004/004116 patent/WO2004074437A2/en not_active Ceased
- 2004-02-13 JP JP2006503521A patent/JP2006517970A/ja active Pending
- 2004-02-13 US US10/779,267 patent/US8795672B2/en not_active Expired - Fee Related
- 2004-02-13 EP EP04711085A patent/EP1599572A4/en not_active Ceased
-
2007
- 2007-02-13 US US11/674,569 patent/US8545838B2/en not_active Expired - Fee Related
-
2013
- 2013-04-18 US US13/865,902 patent/US20140099305A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006517970A5 (enExample) | ||
| DeVita et al. | The chemotherapy of lymphomas: looking back, moving forward—the Richard and Hinda Rosenthal Foundation award lecture | |
| Valent et al. | Immunotherapy-based targeting and elimination of leukemic stem cells in AML and CML | |
| EP3057991B1 (en) | Chimeric antigen receptor t cell switches and uses thereof | |
| Wu et al. | Coiled-coil based drug-free macromolecular therapeutics: in vivo efficacy | |
| ES2981745T3 (es) | Agentes de señalización biespecíficos y usos de los mismos | |
| Mack et al. | The next generation of antibody drug conjugates | |
| Uricoli et al. | Engineered cytokines for cancer and autoimmune disease immunotherapy | |
| KR20230147740A (ko) | Pd-1/pd-l1 억제제 | |
| JP2016509582A5 (enExample) | ||
| WO2016154621A1 (en) | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF | |
| JP2017507936A5 (enExample) | ||
| CA2516028A1 (en) | Conjugates comprising a cancer targeting molecule linked to a liver-expressed chemokine | |
| WO2006050172A3 (en) | Combination cancer immunotherapy with co-stimulatory molecules | |
| Quiles et al. | Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy | |
| RU2017144606A (ru) | Иммуноцитокины на основе il-15 и il-15rа домена sushi | |
| JP2018510132A5 (enExample) | ||
| JP2025072462A (ja) | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 | |
| JP2012102122A5 (enExample) | ||
| AR042977A1 (es) | Formulaciones farmaceuticas liquidas de palonosetron | |
| KR20160022370A (ko) | 면역요법을 위한 조성물 및 방법 | |
| Safdari et al. | CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies | |
| CN111971060A (zh) | 募集抗体并靶向肿瘤细胞的双功能分子 | |
| JP2025527534A (ja) | 抗－ヒト表皮成長因子受容体２（ｈｅｒ２）キメラ抗原受容体（ｃａｒ）を含むナチュラルキラー細胞を投与する方法 | |
| Hutchinson et al. | Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma |